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Integrated data analysis reveals potential
drivers and pathways disrupted by DNA
methylation in papillary thyroid carcinomas
Caroline Moraes Beltrami1†, Mariana Bisarro dos Reis1,2†, Mateus Camargo Barros-Filho1,
Fabio Albuquerque Marchi1, Hellen Kuasne1,2, Clóvis Antônio Lopes Pinto3, Srikant Ambatipudi4, Zdenko Herceg4,
Luiz Paulo Kowalski1,5 and Silvia Regina Rogatto2,6*
Abstract
Background: Papillary thyroid carcinoma (PTC) is a common endocrine neoplasm with a recent increase in
incidence in many countries. Although PTC has been explored by gene expression and DNA methylation studies,
the regulatory mechanisms of the methylation on the gene expression was poorly clarified. In this study, DNA
methylation profile (Illumina HumanMethylation 450K) of 41 PTC paired with non-neoplastic adjacent tissues (NT)
was carried out to identify and contribute to the elucidation of the role of novel genic and intergenic regions
beyond those described in the promoter and CpG islands (CGI). An integrative and cross-validation analysis were
performed aiming to identify molecular drivers and pathways that are PTC-related.
Results: The comparisons between PTC and NT revealed 4995 methylated probes (88% hypomethylated in PTC)
and 1446 differentially expressed transcripts cross-validated by the The Cancer Genome Atlas data. The majority
of these probes was found in non-promoters regions, distant from CGI and enriched by enhancers. The integrative
analysis between gene expression and DNA methylation revealed 185 and 38 genes (mainly in the promoter and
body regions, respectively) with negative and positive correlation, respectively. Genes showing negative correlation
underlined FGF and retinoic acid signaling as critical canonical pathways disrupted by DNA methylation in PTC.
BRAF mutation was detected in 68% (28 of 41) of the tumors, which presented a higher level of demethylation
(95% hypomethylated probes) compared with BRAF wild-type tumors. A similar integrative analysis uncovered 40
of 254 differentially expressed genes, which are potentially regulated by DNA methylation in BRAFV600E-positive
tumors. The methylation and expression pattern of six selected genes (ERBB3, FGF1, FGFR2, GABRB2, HMGA2, and
RDH5) were confirmed as altered by pyrosequencing and RT-qPCR.
Conclusions: DNA methylation loss in non-promoter, poor CGI and enhancer-enriched regions was a significant
event in PTC, especially in tumors harboring BRAFV600E. In addition to the promoter region, gene body and 3’UTR
methylation have also the potential to influence the gene expression levels (both, repressing and inducing). The
integrative analysis revealed genes potentially regulated by DNA methylation pointing out potential drivers and
biomarkers related to PTC development.
Keywords: Papillary thyroid cancer, DNA methylation, Integrative analysis, FGF signaling pathway, Retinoic acid
pathway, BRAFV600E mutation
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Background
Thyroid cancer is the most common tumor of the head
and neck region, with the highest incidence among the
endocrine neoplasias [1]. Papillary thyroid cancer (PTC) is
the histological subtype with higher incidence (80% of
cases) worldwide [2].
The thyroid carcinogenesis involves a constitutive
activation of two major pathways associated to tyrosine-
kinase, including mitogen-activated protein kinase (MAPK)
and phosphatidylinositol 3-kinase (PI3K) [3]. The activation
of these pathways occurs mainly due to point mutations in
BRAF and RAS and chromosomal rearrangements in RET
[3]. MAPK signaling pathway activated by genetic alter-
ations is frequently involved in cell proliferation, growth,
and survival [4].
Approximately 60% of PTC cases are characterized by
T1799A BRAF transversion nucleotide change (over 95%
of the mutations), resulting in V600E mutant protein
with constitutive activation of BRAF kinase [5–7]. BRAF
mutation has been associated with unfavorable prognosis
including large primary tumors, lymph node and vascu-
lar invasion, advanced stage, extrathyroidal extension,
distant metastases, and recurrence [8, 9]. However, there
are no consensus in literature, since many studies have
not found this association [10–12].
The methylation pattern of several genes has been
assessed in PTC, and most of them plays a role in thyroid
gland function (TSHR) [13] and iodine metabolism (NIS
and SLC26A4) [14] or acts as a tumor suppressor gene
(RASSF1A, TIMP3, and RARβ2) [15, 16]. In addition, an
association between BRAFV600E mutation and aberrant
DNA methylation profile has been reported in thyroid
cancer [17–21].
Recently, large-scale approaches were used to investigate
the methylation profile of thyroid cancer [17–23]. These
technologies allow the assessment of not only CpG islands
(CGI) and promoter regions, as previously reported, but
unveiled novel regions involved in neoplastic process,
such as CGI shores/shelf, non-CGI promoter and
enhancers [24, 25]. However, the methylation as a regula-
tory mechanism of gene expression is poorly explored in
PTC, even in the multiplatform robust study performed
by The Cancer Genome Atlas (TCGA) [21].
To our knowledge, the current study is the first to assess
a substantial matched-sample subset with methylation
and expression data addressing the available data from
TCGA study to cross-validate the results. The genes
signature potentially regulated by methylation inferred the
role of this epigenetic event in PTC development.
Methods
Sample population
Snap frozen PTC samples stored at tissue biobank of the
A.C. Camargo Cancer Center, SP, Brazil, were obtained
retrospectively. Forty one papillary thyroid carcinomas of
patients treated with total thyroidectomy followed by
radioiodine therapy and matched non-neoplastic adjacent
tissues (NT) samples were included in this study. Cases
with incomplete clinical data in medical records or diag-
nosed with previous or synchronic malignancies were
excluded (except basal skin cell carcinoma). Clinical and
histopathological data are summarized in Table 1.
Nucleic acids extraction and analysis of somatic
mutations
Genomic DNA extraction was performed according to
conventional protocol using enzymatic degradation with
proteinase K followed by purification with organic solvents
(phenol/chloroform). RNA was isolated as previously
reported [26].
Somatic point mutations of BRAF (codon 599), KRAS
(codon 12/13), HRAS (codon 61), and NRAS (codon 61)
were evaluated by pyrosequencing using a Pyromark Q96
ID system (Qiagen, Valencia, CA, USA). RET rearrange-
ments (RET/PTC1 and RET/PTC3) were detected by
RT-qPCR on a 7500 Real Time PCR System (Applied
Biosystems, Foster, CA, USA) (detailed in Additional file 1).
DNA methylation and gene expression profiling
Five hundred nanograms of DNA (Qubit® dsDNA BR
Assay no Qubit® 2.0 Fluorometer (Life Technologies,
Carlsbad, CA, USA) were bisulfite-modified using
EZ-DNA Methylation-Gold Kit (Zymo Research, Irvine,
CA, USA) according to the manufacturer’s recommen-
dations. Converted DNA was used for the genome-wide
methylation assays (Infinium Human Methylation450
BeadChip array-Illumina, San Diego, CA, USA). Arrays
were scanned by HiScan system (Illumina), and methylation
data were analyzed as β values. Genome-wide DNA methy-
lation data processing was done as reported previously [27]
(detailed in Additional file 1). Limma package [28] was used
to identify significant probes adopting adjusted (Bonferroni)
p value <0.05 and mean delta β value (Δβ) of 0.15 as a
threshold for differential DNA methylation. A hypergeo-
metric test (p < 0.05) was performed from phyper function
of STATS package in R language to compare differentially
methylated probes in relation to genomic regions (Illumina
450K array annotation).
Gene expression data were obtained from our previously
reported study (GEO accession number GSE50901) [26].
The unsupervised hierarchical clustering analysis was
performed using the most variable probes (interquartile
range >0.2 to methylation and >1.0 to gene expression).
Euclidean distance with average linkage method was used
in all clustering analysis by BRB array tool software
(https://brb.nci.nih.gov/BRB-ArrayTools/download.html).
Student t test was assessed to verify the association
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between methylation/expression data of selected genes
with clinical parameters.
Integrative analysis and cross-study validation
All probes differentially methylated (|Δβ| 0.15 and
adjusted p < 0.05) and expressed (FDR <5% and fold
change >2) were subjected to an integrative analysis,
using a Pearson correlation test (34 PTC evaluated by
both analysis), aiming to obtain negative and positive
significant correlations (p < 0.05).
A cross-study validation was performed to confirm the
results using DNA methylation microarray and RNA
sequencing data from TCGA database (https://tcga-
data.nci.nih.gov/docs/publications/tcga/). Similar param-
eters of the internal analysis were adopted to compare
all conditions in the external dataset (t test p < 0.05, FDR
<5% and Pearson correlation test p < 0.05) (details in
Additional file 1). Figure 1 summarizes the strategy and
results obtained in this analysis.
In silico molecular interactions analysis
Disease and biological function and canonical pathway
analysis including genes found in the integrative ana-
lysis were performed using Ingenuity pathway analysis
(IPA-Ingenuity® Systems) and KEGG Orthology Based
Annotation System (KOBAS—http://kobas.cbi.pku.edu.cn/)
software version 2.0. Genes confirmed by TCGA database
with negative correlation between expression and methyla-
tion probes were included to obtain a highly trustworthy
analysis.
Data confirmation by quantitative bisulfite
pyrosequencing and RT-qPCR
In addition to the independent data confirmation using
TCGA database, four genes (ERBB3, FGF1, GABRB2, and
HMGA2) presenting methylation in the body gene region
and two in the promoter regions (FGFR2 and RHD5) were
selected to be evaluated for quantitative bisulfite pyrose-
quencing and RT-qPCR analysis. The selection criteria of
these genes are presented in Additional file 1.
The CpG methylation pattern was assessed by quantita-
tive bisulfite pyrosequencing using the Pyromark Q96 ID
system (Qiagen, Valencia, CA, USA) in samples
Table 1 Clinicopathological features of 41 patients diagnosed
with papillary thyroid carcinoma
Characteristics Number Frequency (%)
Age (years)
Median (interquartile range) 39(20-77)
<55 34 83
≥55 7 17
Gender
Female 30 73
Male 11 27
Size Tumor (cm)
Median (range) 1.2(0.6-3.2)
mPTC (≤1) 18 44
PTC (>1) 23 56
Predominant variant
Classic 29 71
Follicular 7 17
Othera 3 7
Not available 2 5
Multicentricity
No 17 41
Yes 24 59
Extrathyroidal extension
No 20 49
Yes 21 51
Lymph Nodes involvement
No 25 61
Yes 16 39
Angiolymphatic invasion
No 39 95
Yes 1 5
Perineural invasion
No 36 88
Yes 2 5
Not available 3 7
Outcome
Favorableb 36 88
Poor c 5 12
Follow-up
>5 years 36 88
<5 years 5 12
Somatic alterations
BRAF mutation 28 68
BRAF wild-type 13 32
RAS mutation 0 0
Table 1 Clinicopathological features of 41 patients diagnosed
with papillary thyroid carcinoma (Continued)
RAS wild-type 41 100
RET/PTC inversion 5 12
RET/PTC wild-type 36 88
mPTC Papillary thyroid microcarcinoma
aThree rare variants were grouped: one tall cells, one oncocytic, and
one mucosecretory
bPatients without any suspicion of active disease by imaging scan and/or
serum thyroglobulin measurement in at least 5 years of follow-up
cPatients with confirmed recurrent disease in the follow-up
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microarray dependent (28 NT and 29 PTC) and inde-
pendent (24 NT and 76 PTC). Gene expression analysis
was performed by RT-qPCR in a 7500 Real Time PCR
System (Applied Biosystems, Foster, CA, USA) in samples
used in the microarray assays (4NT and 51 PTC) and in an
independent set of cases (48NT and 54 PTC). The details
of both procedures are presented in Additional file 1.
The pyrosequencing and RT-qPCR results were
compared to tumor/normal status and according to
clinical, pathological and genetic features by Student’s t test
(p < 0.05) using GraphPad Prism 5.0 Software (Inc., La Jolla,
CA, USA). Bonferroni correction was applied to adjust the
P value by multiple hypotheses testing.
Results
DNA methylation and gene expression profiles in PTC
To identify differential methylation in PTC, we analyzed
CpG methylation status comparing PTC with NT (p < 0.05;
|Δβ| 0.15). This analysis revealed 6070 CpGs probes
differentially methylated, of which 89% (5425) were
hypomethylated. A supervised hierarchical clustering
analysis revealed two main clusters, one comprised
exclusively PTC samples and the other included all NT
and six PTC cases (Fig. 2a).
A total of 4995 of 6070 available probes in the TCGA
database was confirmed as differentially methylated
(Additional file 2: Table S1, Additional file 3: Figure S1A),
highlighting the robustness of our methylome analysis. An
enrichment of the identified probes was detected in non-
promoter regions (76 vs. 59% represented by the platform,
p < 0.0001), mapped far from the CpG island called “open
sea” (66 vs. 33% represented by the platform, p < 0.0001),
and enhancers regions (54 vs. 21% represented by the
platform, p < 0.0001) (Fig. 2b).
Using our previous genome-wide expression data [26] in
61 PTC versus five NT, 1657 differentially expressed genes
Fig. 1 Workflow representative of the strategy used in the integrative analyses and in the cross-study validation. a Genome-wide methylation analysis
revealed 6070 differentially methylated probes, and large-scale gene expression analysis identified 1657 differentially expressed genes in PTC (the last
from a previous study). Corresponding probes/genes were submitted to a Pearson correlation test (34 PTC analyzed by both platforms) revealing 214
genes presenting probes with negative correlation and 49 genes with positive correlation. A total of 247 genes were classified as potentially regulated
by DNA methylation in PTC. b A total of 4563 differentially methylated probes and 333 differentially expressed genes were identified in PTC according
to BRAFV600E mutation. The Pearson correlation test revealed 69 and 17 genes with negative and positive correlation, respectively. Eighty three genes
were classified as potentially regulated by DNA methylation in PTC BRAF mutated. *Tumor samples were initially corrected by NT samples
(ΔβPTC-ΔβNT) and then BRAF positive and negative tumors were compared; §Some genes presented both methylation probes negatively
and positively correlated. #Unadjusted p value
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were found (FDR <5% and FC >2). The comparison of these
results with TCGA database, confirmed the involvement
of 1446 genes differentially expressed (Additional file 4:
Table S2, Additional file 3: Figure S1B).
Integration of DNA methylation and gene expression
profiles in PTC
A powerful tool used in the identification of novel driver
alterations in cancer is the combined analysis of different
Fig. 2 Classification of the differentially methylated probes in PTC. a Supervised hierarchical clustering analysis showed 6070 differentially
methylated probes in papillary thyroid carcinoma (PTC) versus normal thyroid (NT) tissues, mostly hypomethylated in PTC. The first cluster
shows all normal samples (purple) and six PTC (orange), and the second is composed exclusively by tumor samples (orange). The beta
values vary between zero (green) and one (red). b Methylation probes identified in PTC versus NT and those detected in the integrative
analysis with negative (r−) and positive correlation (r+) according to the functional genomic distribution, CpG content, and neighborhood
context and enhancer representation
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molecular platforms (21). Accordingly, an integrative
DNA methylation and gene expression analysis were
performed, highlighting genes potentially regulated by
DNA methylation. The methylation analysis revealed
867 probes representing 420 genes differentially expressed.
A total of 214 and 49 genes were identified as negatively
and positively correlated (185 and 38 confirmed in the
TCGA), respectively, with the corresponding methylation
probe (Additional file 5: Table S3). Curiously, about half of
the negatively correlated probes (163) was found covering
promoter regions and 2% were mapped in CpG islands,
contrasting to only 10% (6) of the positively correlated
probes in promoter regions (p < 0.0001) and 21% (11) in
CpG islands (p < 0.0001). No differences were observed in
the enhancer regions (p = 0.299) (Fig. 2b).
The genes uncovered by the integrative analysis (nega-
tively correlated and confirmed as altered in the TCGA
portal) were distributed through all autosomal chromo-
somes (Fig. 3a). Cellular movement, growth, proliferation,
and survival were the most significant molecular functions
(IPA software) involving these genes (Additional file 6:
Table S4). The FGF (Additional file 3: Figure S2) and
retinoic acid signaling (IPA and KOBAS 2.0, p < 0.01) were
among the main canonical pathways involved in PTC
(Additional file 6: Table S4).
DNA methylation and gene expression profiling
according to BRAF mutation
The BRAF (BRAFV600E) point mutation was detected
in 28 of 41 PTC (68%) while no RAS (HRAS, KRAS,
and NRAS) mutations were observed. The RET rear-
rangements (RET/PTC1 and RET/PTC3) were found in
five of 41 cases (12%). As expected, the alterations were
mutually exclusive.
An unsupervised hierarchical clustering analysis,
comprising 34 PTC evaluated by both methylation and
expression arrays, revealed two distinct clusters (Fig. 3b, c).
A substantial overlapping between methylation and expres-
sion clusters was observed. One cluster was enriched by
BRAFV600E tumors in methylation and expression analysis
(p = 0.034 and p = 0.013, respectively, Fisher’s exact test).
Fig. 3 Methylation and gene expression profiling in PTC. a Genes identified in the integrative analysis with negative correlation and confirmed in
the TCGA data. The outermost circle displays the human autosomal chromosomes, and the inner layers show both expression and methylation
profiles. The figure was created following the parameters available in http://circos.ca. Unsupervised hierarchical clustering analysis revealed the b
methylation and c gene expression profiles of 34 PTC evaluated with both platforms, and the relation with histological variant, genetic alteration,
and follow-up. Two clusters were identified by both methodologies, and an overlapping between methylation and expression data was observed
(dark and gray clustering). Gray cluster of methylation and gene expression was associated with a higher frequency of BRAF-mutated tumors (p = 0.034
and p = 0.013, respectively; Fisher’s exact test)
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The importance of BRAF mutation in the methylation
and expression profiles was evaluated using a similar
approach described in the integrative analysis using PTC
versus NT samples. A differential methylation profile
(unadjusted p < 0.05; |Δβ| 0.1) was observed in PTC
BRAF mutated (3312 hypomethylated and 1251 hyper-
methylated probes) compared with PTC BRAF wild-type
(Additional file 7: Table S5). The expression profile
unveiled 333 altered transcripts in BRAF-mutated tumors
(FDR <5% and FC >1.5) (Additional file 8: Table S6).
The comparison with TCGA database showed similar
methylation and gene expression pattern in 29 and 82%
of the genes, respectively. Integrative analysis revealed
69 and 17 genes with significant negative and positive
correlation (36 and 5 of them were also found in the
TCGA), respectively (Additional file 9: Table S7).
Validation of genes potentially regulated by methylation
and association with clinical features
The genes investigated by pyrosequencing and RT-qPCR
(selected from the integrative analysis and TCGA
cross-study validation) were confirmed as differentially
methylated/expressed, showing inverted methylation and
expression patterns. ERBB3 (p = 0.0005), FGF1 (p < 0.0001),
GABRB2 (p < 0.0001), HMGA2 (p < 0.0001), and RDH5
(p < 0.0001) genes were hypomethylated and over-
expressed (p < 0.0001). Moreover, FGFR2 was hypermethy-
lated and downexpressed (p < 0.0001 and p < 0.0001,
respectively) (Fig. 4a, b). Increased expression of ERBB3
(p < 0.0001) and GABRB2 (p < 0.011) and hypomethylation
of FGF1 (p = 0.0003), GABRB2 (p < 0.014), and RDH5
(p < 0.016) were significantly associated with BRAF-mu-
tated tumors (Additional file 3: Figure S3). No signifi-
cant association was detected in the comparison between
clinical parameters and the markers evaluated by both RT-
qPCR and pyrosequencing (Bonferroni-adjusted p > 0.05)
(Additional file 10: Table S8).
Discussion
The purpose of this study was to characterize the DNA
methylation pattern of PTC and to elucidate its effect on
gene expression deregulation and the biological path-
ways associated with the disease. By comparing PTC
with matched NT, a global hypomethylation was
detected, as previously reported [19, 20, 23]. Loss of
DNA methylation throughout the genome has been
related to genomic instability, somatic driver mutations,
chromosomal breaks, and rearrangements. Papillary thy-
roid tumors have been characterized by a low number of
structural rearrangements and frequent somatic driver
mutations [17, 19, 20, 23].
CpG islands (CGI) are well described in literature as
often found in promoters and associated with gene
downregulation when hypermethylated [25]. In our
study, half of the methylated probes presenting inverted
patterns compared with gene expression (negative
Fig. 4 Methylation (a) and expression levels (b) confirmation of the selected genes. a ERBB3, FGF1, GABRB2, HMGA2, and RDH5 hypomethylation
and FGFR2 hypermethylation were confirmed in PTC samples by pyrosequencing after DNA modification by bisulfite. b. ERBB3, FGF1, GABRB2,
HMGA2, and RDH5 overexpression and FGFR2 downexpression were confirmed in PTC by RT-qPCR. The boxplot indicates the interquartile range
and median. ***p < 0.001 by comparing PTC to NT (Student’s t test)
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correlation) were annotated in promoters, contrasting
with only 10% of probes showing positive correlation.
Recently, epigenetic studies have uncovered that methy-
lation alterations at other regulatory regions such as
CGI shores, non-CGI promoter, and enhancers might
also play a role in tumorigenesis [17–23, 25]. In our
study, these regions were more frequently detected,
agreeing with previous reports in PTC samples [20].
Gene bodies are reported as having a limited number
of CpG islands and broadly methylated. Interestingly,
this region harbors multiple repetitive and transposable
elements [25]. However, the biological significance of
DNA methylation in this region is poorly clarified. Gene
body methylation does not necessarily block the
transcription as observed in promoter regions, but might
increase the transcriptional activity, stimulate the tran-
scription elongation, and impact in the splicing [25, 29].
Accordingly, 80% of the probes presenting positive cor-
relation between methylation/expression were annotated
in gene body or 3’UTR. Interestingly, differentially meth-
ylated probes exclusively mapped in body or in promoter
regions presented a similar proportion of differentially
expressed genes (14 and 18%, respectively). Furthermore,
an opposite relation between methylation and expression
(hypomethylation/overexpression or hypermethylation
/downexpression) of probes mapped exclusively in the
promoter or in body gene regions were also detected
(73 and 93%, respectively). These findings suggest that
body gene methylation is a process involved in gene
expression regulation, similar to those described in the
promoter regions.
From 1446 genes differentially expressed (internal and
external data), only 212 were considered as regulated by
DNA methylation, suggesting the involvement of other
transcription-regulator mechanisms. Nonetheless, one of
the most significant results herein described was the
enrichment of methylation disruption in enhancer
regions (54% of the methylated probes). Enhancers are
non-coding regulatory sequences able to recruit tran-
scription factors and activate promoters. These regions
are located from a few kilobases to more than a mega-
base of the transcription start site of the target gene
[30]. Although the exact mechanism of the regulatory
proteins binding according to DNA methylation in
enhancers is still unclear, hypomethylation seems to result
in increased activity of the target gene [31]. Therefore,
even if only a few genes were directly associated with the
regulation of DNA methylation, several genes might be
influenced by the altered methylation in enhancer regions.
Aran and Hellman [32] suggested that gene expression
variation could be explained by methylation in enhancers.
The in silico analysis comprising 185 genes found in
the integrative analysis (inverted methylation/expression
pattern and confirmed by the cross-study validation)
highlighted the importance of epigenetic alterations in
thyroid carcinogenesis. The predicted effects in the
biological functions (cellular movement, growth, prolifera-
tion, and survival) were previously reported as associated
with thyroid cancer development [33]. Furthermore,
deregulated canonical pathways including the retinoic
acid- and FGF signaling pathways were unveiled as associ-
ated to PTC. The retinoic acid (RA) is involved in cell
differentiation and plays a fundamental role in preventing
neoplastic growth [34]. The RA biosynthesis involves the
RDH5 enzyme, which reversibly oxidizes all-trans-
retinol to all-trans-retinaldehyde and them irreversibly
oxidized to RA by retinoid-active aldehyde enzymes
(ALDH1A) [35, 36]. We found RDH5 hypomethylation
and overexpression and ALDH1A1 downexpression in
PTC, suggesting a dysregulation of RA metabolism.
Retinoic acid has been implicated in re-differentiation of
thyroid cells by the induction of sodium-iodide symporter
(NIS) expression, which is responsible for the iodine
internalization [37, 38]. Loss of NIS expression has been
associated to a low uptake of iodine and interference in
the efficacy of the radioiodine therapy in thyroid tumors
[39]. According to our results, the methylation changes
are potentially involved in the dedifferentiation of PTC
cells, as a result of RA signaling pathway disruption.
Fibroblast growth factor signaling pathway, involved in
angiogenesis and tumorigenesis [40], was significantly
altered in our PTC samples. FGF1 and FGF2 have been
reported as over-expressed in differentiated thyroid
tumors, but their receptors present contrasting results
[41–43]. In our study, FGF1 was found hypomethylated
and over-expressed and FGFR2 was hypermethylated
and downexpressed. According to Kondo et al, FGFR2
hypermethylation promotes downexpression and its
re-expression acts blocking the BRAF/MAPK pathway in
thyroid cancer [44].
Similar to the literature, mutually exclusive somatic
alterations were found in BRAF (68% of PTC samples)
and RET (12%), while RAS had no mutations [18, 45,
46]. The supervised clustering analysis of the methyla-
tion profiling revealed six PTC grouped with NT sam-
ples, two of them were BRAFV600E and one RET-PTC3
positive. The inclusion of PTC samples in NT enriched
clusters was previously reported in methylation profiling
studies [19]. This finding could be explained by non-
tumor cells contamination, as also observed in the
TCGA study [21].
The hierarchical clustering analysis showed a substantial
overlapping between transcripts and methylation profiles.
A cluster enriched with of BRAFV600E tumors was
detected, in agreement with previous studies using methy-
lation [20] and gene expression analysis [45]. Kikuchi et al
[18] evaluated the methylation profile (Infinium Human-
Methylation27K Illumina) of 14 PTC and 10 normal
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thyroid tissues. Among the 25 differentially methylated
genes, six (HIST1H3J, POU4F2, SHOX2, PHKG2, TLX3,
and HOXA7) were selected for data confirmation. The
authors described hypermethylation and downexpression
of these genes in an additional set of cases and an associ-
ation with BRAF/RAS mutations. From these genes, only
PHKG2 was found hypomethylated (promoter region) of
our gene list. The supervised analysis revealed an even
more evident hypomethylated state in tumors harboring
BRAFV600E, where 73% of the probes were less
methylated compared to wild-type BRAF tumors (95%
considering the TCGA confirmed probes). The integrative
analysis according to BRAF mutation uncovered 69 genes
showing negative correlation, 36 of them were confirmed
by external data (TCGA). Similarly, Mancikova et al [19]
reported genes with inverse correlation between methyla-
tion and gene expression mainly associated to MAPK
pathway (MAPK13, DUSP5, and RAP1GA1) and apoptosis
(LCN2, RIPK1, and LGALS1). The stratification of PTC
into two entities, the BRAF-like (classical or tall variant)
and RAS-like (composed mainly by the follicular variant),
based on molecular landscape was generated from omics
integrative analysis in a cohort of 496 PTCs [21]. Consid-
ering only the DNA methylation levels, the authors
described four groups, two of them enriched by H/K/
NRAS-mutated follicular variant PTC (follicular and CpG
island methylated) and two enriched by BRAF-mutated
classical and tall cell PTC (classical 1 and classical 2).
Similar to our findings, composed largely by BRAF-mu-
tated tumors, the TCGA classical/tall cell PTC-enriched
cluster was distinguished by low levels of methylation in
CpG normally methylated outside of islands [21].
In addition to RDH5 (RA pathway), FGF1, and FGFR2
(both from FGF signaling pathway), ERBB3, GABRB2,
and HMGA2 were previously reported as over-expressed
in PTC [43–49]. Methylation and expression pattern of
these genes were also confirmed by pyrosequencing and
RT-qPCR. Previously, we pointed out GABRB2 and
HMGA2 as potential diagnostic makers in thyroid
tumors [26]. HMGA2 interacts with the transcription
machinery (acts in the chromatin structure and regulates
the transcription) and in the epithelial-mesenchymal
transition (by repression of E-cadherin) [47, 50, 51].
Although HMGA2 and GABRB2 were not associated
with clinical features or somatic alterations in the large-
scale expression analysis, the independent validation
demonstrated that GABRB2 hypomethylation and over-
expression were significantly altered in BRAFV600E
tumors. Tumors harboring this mutation were associated
with ERBB3 overexpression [45, 48] but not with DNA
methylation. A plausible explanation is the involvement
of different mechanisms associated with the ERBB3
regulation in BRAF tumors, including the involvement
of miRNAs or other post-transcription regulation events
[49, 52]. Overexpression and oncogenic activation of
ERBB3 have been associated to treatment resistance with
RAF/MEK inhibitors in melanoma and thyroid cancer,
especially in the specific context of BRAFV600E [53–55].
Conclusions
Papillary thyroid cancer was largely characterized by
methylation loss, mainly in BRAFV600E PTC. The
alterations were distributed throughout the genome, albeit
overrepresented by enhancers. Promoter region deregula-
tions were related to an inverse pattern of gene expression
levels as expected, while non-promoter regions consisted
by both negative and positive correlations. The integrative
analysis combined with a cross-study validation allowed the
identification of genes acting in essential pathways associ-
ated with PTC pathogenesis and progression. Furthermore,
potential drivers, therapeutic targets, and biomarkers are
highlighted, which could be useful in the management of
PTC patients.
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